FOLFIRI方案治疗晚期结直肠癌的近期疗效观察

An Overview of Clinical Efficacy of FOLFIRI Regimen in Patients with Advanced Colorectal Cancer.

目的评价FOLFIRI方案治疗晚期结直肠癌的临床疗效及毒副反应。方法入组32例，可评价疗效29例，方案用法为开普拓（CPT-11）180mg／m。静滴，第1天，亚叶酸钙（CF）200mg／m^2静滴，第1～2天，5．氟尿嘧啶（5-Fu）400mg／m。静推，随后5-Fu600mg／m^2静滴22h，第1～2天，14d为1个周期，3个周期（6周）评价疗效。结果CR2例，PR10例，SD13例，PD5例，有效率为41．4％（12／29）。主要毒副反应为迟发性腹泻（Ⅲ°／Ⅳ°发生率为9．4％）及中性粒细胞减少（Ⅲ°／Ⅳ°发生率为12．5％）。结论FOLFIRI方案治疗晚期结直肠癌有效率高，安全性好，可作为晚期结直肠癌的一线或二线化疗方案。

Objective To evaluate the clinical efficacy and adverse effects of FOLFIRI regimen in treatment ofadvanced colorectal cancer, Methods 32 patients with advanced colorectal cancer received therapy, 29 cases were evaluable for efficacy, Regimen： CPT-11 180mg/m^2 ivgtt dl, CF 200 mg/m^2 ivgtt followed by 5-Fu 400 mg/m^2 iv and 5-Fu 600mg/m2 ivgtt 22 hoars, dl ~2, a cycle was 14 days.After 3 cycles the efficacy was evaluated. Results 29cases could evaluate efficacy, the complete response and partial response were observed in 2 and l0 cases respectively, the overall response rate was 41A%, Dose limiting toxicity （DLT） was delayed diarrhea and neutropenia. Conclusion The efficacy of FOLFOLI regimen in treatment of advanced colorectal cancer was high and safety.